Earnings call transcript: Sandoz Q1 2026 results show strong biosimilar growth

Sandoz posted Q1 2026 net sales of $2.8 billion, up 11% year over year, with biosimilar sales rising 18% to $0.9 billion and representing 31% of total sales. The company reaffirmed full-year guidance for mid- to high-single-digit constant-currency sales growth and around 100 bps of core EBITDA margin expansion, while shares jumped 8.81% on the results. Management also highlighted strong launches, a 4% FX tailwind for the year, and an improved debt profile extending maturities to 2036.

Analysis

The market is still underestimating how much of Sandoz’s earnings mix is being re-rated by biosimilars, not just growing. The key second-order effect is that each incremental biosimilar launch improves both mix and negotiating leverage, while generics are being deliberately de-emphasized where returns are weakest; that can support gross margin even if headline growth later normalizes. This is why the business can look like a mid-single-digit top-line story yet still deliver disproportionate EPS upside if launch cadence stays intact.

The bigger signal is not the current quarter but the forward inventory of catalysts: the company has effectively created a multi-year ladder of U.S./Europe launches that should reduce dependence on any single molecule. That lowers event risk versus the usual biosimilar model, where a missed tender or slower physician uptake can break the thesis. It also means competitors with narrower pipelines face a more fragile P&L, especially if they need one or two products to carry the portfolio.

The contrarian point is that consensus may be too focused on near-term share gain in individual assets and not enough on value capture. In biosimilars, volume share can be a trap if discounting accelerates; the better indicator is whether Sandoz can preserve ASP while broadening access. If that discipline holds, the earnings power compounds for several quarters; if not, the setup shifts from growth story to race-to-the-bottom pricing, most likely over the next 6-12 months as new entrants scale.

FX is a hidden near-term booster, but it is also a valuation trap: the stronger currency tailwind lifts reported sales now and can mask weaker organic price realization. If the market extrapolates the reported print, the stock can overshoot; if the FX boost fades in H2 while generics headwinds truly wash out, the equity should re-rate on margin durability rather than top-line noise.

Key Decisions for Investors

• Long 0SAN on a 1-3 month horizon into the next biosimilar launch window; use a 5-8% pullback as entry. Risk/reward favors upside if management keeps ASP discipline, with downside mostly limited to a normal post-earnings fade.
• Pair trade: long 0SAN vs short a weaker, more concentrated biosimilar/generic peer basket over 3-6 months. Thesis is that Sandoz’s breadth and pipeline reduce single-asset risk while competitors remain more exposed to price compression and execution misses.
• Buy 0SAN call spreads 3-6 months out rather than outright equity if you want exposure to launch-driven upside with limited downside. This is best positioned ahead of Q2/Q3 catalyst flow, when reported growth should still be aided by mix and FX.
• Avoid chasing after a strong reported quarter if the stock re-rates above peer P/E without corresponding margin confirmation. The cleaner entry is after the FX tailwind starts to fade and the market can better price organic growth.
• Watch for a relative long against large-cap pharma or generic peers with weaker biosimilar exposure; Sandoz should outperform if investors rotate toward self-help, pipeline optionality, and margin expansion rather than defensive yield.